Results 71 to 80 of about 5,042 (130)

Association of body mass index with clinicopathological features among patients with clear cell renal cell carcinoma treated with surgery: a retrospective study

Scientific Reports
To investigate the potential association between body mass index (BMI) and the clinicopathological features of patients with clear cell renal cell carcinoma (ccRCC).
Zhibin Fu, Yewei Bao, Kai Dong, Di Gu, Zheng Wang, Jiean Ding, Ziwei He, Xinxin Gan, Zhenjie Wu, Chenghua Yang, Linhui Wang   +10 more
doaj   +1 more source

Predictors of ISUP Grade Group Discrepancies Between Biopsy and Radical Prostatectomy: A Single-Center Analysis of Clinical, Imaging, and Histopathological Parameters. [PDF]

Cancers (Basel)
Pasecinic V, Novacescu D, Zara F, Dumitru CS, Dema V, Latcu S, Bardan R, Cumpanas AA, Dumache R, Cut TG, Ismail H, Stana AH.   +11 more
europepmc   +1 more source

Impact of ISUP grade group on cancer-specific mortality in radical prostatectomy-treated prostate cancer patients with organ-confined disease. [PDF]

Can Urol Assoc J
Barletta F, Tappero S, Morra S, Incesu RB, Garcia CC, Piccinelli ML, Scheipner L, Tian Z, Gandaglia G, Stabile A, Mazzone E, Terrone C, Longo N, Tilki D, Chun FKH, de Cobelli O, Ahyai S, Saad F, Shariat SF, Montorsi F, Briganti A, Karakiewicz PI.   +21 more
europepmc   +1 more source

MRI characteristics predict risk of pathological upgrade in patients with ISUP grade group 1 prostate cancer. [PDF]

Eur Radiol
Boschheidgen M, Schimmöller L, Radtke JP, Kastl R, Jannusch K, Lakes J, Drewes LR, Radke KL, Esposito I, Albers P, Antoch G, Ullrich T, Al-Monajjed R.   +12 more
europepmc   +1 more source

MRI characteristics and oncological follow-up of patients with ISUP grade group 4 or 5 prostate cancer. [PDF]

Abdom Radiol (NY)
Boschheidgen M, Schimmöller L, Kastl R, Drewes LR, Jannusch K, Radke KL, Kirchner J, Ullrich T, Niegisch G, Albers P, Antoch G, Radtke JP.   +11 more
europepmc   +1 more source

The 2012 Briganti nomogram not only predicts lymph node involvement but also disease progression in surgically treated intermediate-risk prostate cancer patients with PSA <10 ng/mL, ISUP grade group 3, and clinical stage up to cT2b. [PDF]

Int Braz J Urol
Porcaro AB, Panunzio A, Orlando R, Montanaro F, Baielli A, Artoni F, Gallina S, Bianchi A, Mazzucato G, Serafin E, Patuzzo GM, Veccia A, Rizzetto R, Brunelli M, Migliorini F, Bertolo R, Tafuri A, Cerruto MA, Antonelli A.   +18 more
europepmc   +1 more source

Comparative outcomes of focal HIFU versus active surveillance in low- and intermediate-risk localized prostate cancer: a 75-month retrospective cohort study. [PDF]

Front Urol
Jaabou M, Buscarini M, Zaytoun O, Dovey Z, Hildebrand B, Awan M, Bada M, Al Ogaili M, Rabie A.   +8 more
europepmc   +1 more source

Limited Incremental Diagnostic Value of Perilesional and Systematic Biopsies in PI-RADS 4-5 Lesions: A Retrospective Single-Center Study. [PDF]

Cancers (Basel)
Scarrone E, Canale V, Antonelli L, Stira J, Gravina C, Zarrelli G, Sciarra A.   +6 more
europepmc   +1 more source

The Added Value of Systematic Biopsy in Biopsy-Naïve Patients Undergoing Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Prostate Biopsy. [PDF]

Res Rep Urol
Sawazaki H, Kitamura Y, Asano A, Suzuki S.   +3 more
europepmc   +1 more source

Imaging-based clinical decision tree enables risk stratification of extraprostatic extension before radical prostatectomy in prostate cancer patients. [PDF]

Insights Imaging
Hamm CA, Rüterhenke T, Baumgärtner GL, Mayerosch C, Schallenberg S, Lindholz M, Beetz NL, Asbach P, Penzkofer T.   +8 more
europepmc   +1 more source